S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Your Money is Not Safe (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Your Money is Not Safe (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Your Money is Not Safe (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Your Money is Not Safe (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:ALXN

Alexion Pharmaceuticals (ALXN) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)
Free ALXN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$182.50
▼
$182.50
50-Day Range
$179.45
▼
$186.61
52-Week Range
$99.91
▼
$187.45
Volume
10 shs
Average Volume
3.31 million shs
Market Capitalization
$40.34 billion
P/E Ratio
59.64
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ALXN stock logo

About Alexion Pharmaceuticals Stock (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

ALXN Stock News Headlines

April 2, 2024 | msn.com
Alexion’s Voydeya gains FDA approval for extravascular haemolysis
March 27, 2024 | msn.com
US FDA grants approval for Alexion’s NMOSD treatment
April 19, 2024 | Paradigm Press (Ad)
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
March 19, 2024 | businesswire.com
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
December 11, 2023 | stocknews.com
Citius Pharmaceuticals (CTXR) Earnings Watch: Pharma Stock Signals for Investors
December 8, 2023 | markets.businessinsider.com
Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. (ALXN) an Upcoming Claims Deadline in a Class Action Settlement
November 7, 2023 | investing.com
BioMarin Pharma gains on report Elliott has a stake
November 6, 2023 | stocknews.com
Gilead Sciences (GILD) Earnings Forecast and Gameplan
April 19, 2024 | Paradigm Press (Ad)
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
September 11, 2023 | msn.com
Alexion and Verge enter AI-powered drug discovery deal
May 13, 2023 | investing.com
Alexion Pharmaceuticals Inc (A1LX34)
April 25, 2023 | marketwatch.com
Wilson Disease Drugs Market Size, Growth Strategies, Gross Margin and Forecast 2029
April 10, 2023 | thestreet.com
Alexion Reaches New 52-Week High (ALXN)
March 4, 2023 | stockhouse.com
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
February 9, 2023 | investing.com
AstraZeneca goes for growth with new drugs as COVID sales wane
January 25, 2023 | seekingalpha.com
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
January 21, 2023 | thestreet.com
Synageva Biopharma (GEVA) Stock More Than Doubles to 52-Week High on Alexion Acquisition
October 14, 2022 | finance.yahoo.com
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
September 15, 2022 | lse.co.uk
US close: Dow loses almost 1,300 points after hot CPI reading
September 1, 2022 | thestreet.com
Alexion Stock Hits New 52-Week High (ALXN)
July 29, 2022 | uk.investing.com
FTSE 100 positive but off best levels, US seen higher
March 17, 2022 | markets.businessinsider.com
AstraZeneca's Unit Alexion To Pay $775 Mln To Chugai On Ultomiris Patent Settlement
March 1, 2022 | uk.investing.com
AstraZeneca inks $760 million deal with Swiss firm Neurimmune for antibody drug
January 7, 2022 | msn.com
UK pre-market stocks update – Shell, AstraZeneca, Aston Martin, C&C
November 8, 2021 | finance.yahoo.com
Was The Smart Money Right About Piling Into Microchip Technology Incorporated (MCHP)?
October 26, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)
September 29, 2021 | feeds.benzinga.com
AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M
See More Headlines
Receive ALXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alexion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/29/2021
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALXN
CUSIP
01535110
CIK
899866
Web
www.alexion.com
Phone
475-230-2596
Fax
N/A
Employees
3,837
Year Founded
1992

Profitability

EPS (Most Recent Fiscal Year)
$11.60
Trailing P/E Ratio
59.64
Forward P/E Ratio
13.95
P/E Growth
0.93
Net Income
$603.40 million
Net Margins
10.89%
Pretax Margin
N/A
Return on Equity
23.43%
Return on Assets
15.06%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
4.52
Quick Ratio
3.96

Sales & Book Value

Annual Sales
$6.07 billion
Price / Sales
6.65
Cash Flow
$22.81 per share
Price / Cash Flow
8.00
Book Value
$53.24 per share
Price / Book
3.43

Miscellaneous

Outstanding Shares
221,019,000
Free Float
N/A
Market Cap
$40.34 billion
Optionable
Optionable
Beta
1.25

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

Should I Buy Alexion Pharmaceuticals Stock? ALXN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Alexion Pharmaceuticals, Inc.:

  • Alexion Pharmaceuticals, Inc. has a diverse portfolio of therapeutic products, including ULTOMIRIS and SOLIRIS, targeting rare diseases, which can lead to a strong market presence and revenue growth.
  • The company is actively involved in developing new treatments such as ALXN1210 (Intravenous) and ALXN1210 (Subcutaneous) for various conditions, indicating a commitment to innovation and potential future revenue streams.
  • Recent developments like the Phase III clinical trials of ALXN1840 for Wilson disease demonstrate the company's focus on expanding its product offerings and addressing unmet medical needs.
  • Partnerships and collaborations with other biopharmaceutical companies like Halozyme Therapeutics, Inc. and Dicerna Pharmaceuticals, Inc. can provide access to additional resources, expertise, and potentially accelerate research and development efforts.
  • Considering the current stock price and market trends, investing in Alexion Pharmaceuticals, Inc. may present an opportunity for capital appreciation and potential returns for investors.

Cons

Investors should be bearish about investing in Alexion Pharmaceuticals, Inc. for these reasons:

  • The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring new products to market or maintain profitability.
  • Ongoing clinical trials and research efforts involve inherent risks, including potential delays, failures, or unforeseen complications, which may affect the company's financial performance and investor confidence.
  • Market volatility and macroeconomic factors can influence the stock price of pharmaceutical companies like Alexion Pharmaceuticals, Inc., leading to fluctuations in investment returns and risk exposure.
  • Dependency on a few key products like ULTOMIRIS and SOLIRIS for a significant portion of revenue poses a concentration risk, as any issues with these products could impact the company's financial stability and growth prospects.
  • Changes in healthcare policies, pricing regulations, or reimbursement practices can directly impact the profitability and market access of pharmaceutical companies, potentially affecting Alexion Pharmaceuticals, Inc.'s financial performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 11, 2024. Please send any questions or comments about these Alexion Pharmaceuticals pros and cons to contact@marketbeat.com.

ALXN Stock Analysis - Frequently Asked Questions

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings results on Thursday, April, 29th. The biopharmaceutical company reported $3.52 earnings per share for the quarter, beating analysts' consensus estimates of $3.16 by $0.36. The biopharmaceutical company had revenue of $1.64 billion for the quarter, compared to analysts' expectations of $1.58 billion. Alexion Pharmaceuticals had a trailing twelve-month return on equity of 23.43% and a net margin of 10.89%. The business's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.22 earnings per share.

What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?

43 employees have rated Alexion Pharmaceuticals Chief Executive Officer Ludwig Hantson on Glassdoor.com. Ludwig Hantson has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), Walt Disney (DIS) and Visa (V).

Does Alexion Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Alexion Pharmaceuticals: Achillion Pharmaceuticals, Achillion Pharmaceuticals Inc., Alexion 1609 Partners LP, Alexion Bermuda Holding ULC, Alexion Bermuda II L.P., Alexion Bermuda L.P., Alexion Bermuda Limited, Alexion Bermuda Partners L.P., Alexion Business Services Private Limited, Alexion Delaware Holding LLC, Alexion Europe SAS, Alexion Farmacêutica América Latina Serviços de Administração de Vendas Ltda., Alexion Farmacêutica Brasil Importação e Distribuição de Produtos e Serviços de Administração de Vendas Ltda., Alexion Holding B.V., Alexion Holding LLC, Alexion Ilaç Ticaret Limited Þirketi, Alexion Pharma Argentina SRL, Alexion Pharma Austria GmbH, Alexion Pharma Belgium Sprl, Alexion Pharma Canada Corp., Alexion Pharma Colombia SAS, Alexion Pharma Czech s.r.o, Alexion Pharma Development Unlimited Company, Alexion Pharma Foreign Holdings B.V., Alexion Pharma France SAS, Alexion Pharma GK, Alexion Pharma Germany GmbH, Alexion Pharma GmbH, Alexion Pharma Holding Unlimited Company, Alexion Pharma International Operations Unlimited Company, Alexion Pharma Israel Ltd., Alexion Pharma Italy Sarl, Alexion Pharma Korea LLC, Alexion Pharma LLC, Alexion Pharma Mexico S. de R.L. de C.V., Alexion Pharma Middle East FZ-LLC, Alexion Pharma Netherlands B.V., Alexion Pharma Nordics AB, Alexion Pharma Nordics Holding AB, Alexion Pharma OOO LLC, Alexion Pharma Spain S.L., Alexion Pharma Taiwan LTD, Alexion Pharma UK Ltd., Alexion Pharmaceuticals (Shanghai) Company Limited, Alexion Pharmaceuticals Australasia PTY LTD, Alexion Services Europe Sprl, Alexion Services Latin America Inc., Alexion US Holdings LLC, Alexion US1 LLC, Enobia Pharma Corp., Portola Deutschland GmbH, Portola FRG GmbH, Portola Italia S.r.l., Portola Netherlands B.V., Portola Pharma UK Ltd., Portola Pharmaceuticals Espana S.L, Portola Pharmaceuticals Inc., Portola Pharmaceuticals LLC, Portola Schweiz GmbH, Portola USA Inc., Portola Österreich GmbH, Savoy Therapeutics Corp., Synageva BioPharma Corp., Syntimmune, Syntimmune Ltd., TTM Europe Development AB, Taligen Therapeutics Inc., Wilson Therapeutics, Wilson Therapeutics AB, Wilson Therapeutics Incentive AB, and Wilson Therapeutics USA Inc..
Read More
This page (NASDAQ:ALXN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research